NCT05480644 Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors
| NCT ID | NCT05480644 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Duke University |
| Condition | Brain Tumor, Primary |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2022-12-01 |
| Primary Completion | 2032-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2022-12-01 with a primary completion date of 2032-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this protocol is to create a repository of blood samples from patients diagnosed with primary and metastatic brain tumors who are being seen in the Department of Radiation Oncology at Duke Cancer Center.
Eligibility Criteria
Inclusion Criteria: * Have a confirmed diagnosis of primary or metastatic brain tumor (histology or imaging as appropriate) Exclusion Criteria: * None
Contact & Investigator
Eugene Vaios, MD MBA
PRINCIPAL INVESTIGATOR
Duke University Health System (DUHS)
Frequently Asked Questions
Who can join the NCT05480644 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Brain Tumor, Primary. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05480644 currently recruiting?
Yes, NCT05480644 is actively recruiting participants. Contact the research team at Kaitlin.Bailey@duke.edu for enrollment information.
Where is the NCT05480644 trial being conducted?
This trial is being conducted at Durham, United States.
Who is sponsoring the NCT05480644 clinical trial?
NCT05480644 is sponsored by Duke University. The principal investigator is Eugene Vaios, MD MBA at Duke University Health System (DUHS). The trial plans to enroll 300 participants.